Half-year report · HY
2385.TEDINET S100XKJ6
Period2025-07-01 → 2025-12-31
Filed2026-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2025-07-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Operating income | ¥231m | 2025-07-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | −¥203m | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥238m | 2025-07-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥129m | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥198m | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥195m | 2025-07-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥212m | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥162m | 2025-07-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥211m | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥162m | 2025-07-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥6.7bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥6.8bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥6.6bn | at 2024-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥612m | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥775m | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.1bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.0bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.0bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.0bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.8bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥134m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥558m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥98m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥71m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥389m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥324m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥214,000 | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥172,000 | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥6.19 | 2025-07-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.05 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.5 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 90.8% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.4% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 51
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2025-12-31 | −¥16m |
| Reconciling Itemsreconciling | revenue external | 2025-07-01 → 2025-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2025-12-31 | −¥17m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2025-12-31 | −¥174m |
| Clinical Evidence Servicereportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥131m |
| Clinical Evidence Servicereportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥131m |
| Clinical Evidence Servicereportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥11m |
| Functional Cosmetic Retailingreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥726m |
| Functional Cosmetic Retailingreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥725m |
| Functional Cosmetic Retailingreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥919,000 |
| Functional Cosmetic Retailingreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥83m |
| Functional Food Retailingreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥933m |
| Functional Food Retailingreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥926m |
| Functional Food Retailingreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥7m |
| Functional Food Retailingreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥217m |
| Functional Material Developmentreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥180m |
| Functional Material Developmentreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥171m |
| Functional Material Developmentreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥9m |
| Functional Material Developmentreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥19m |
| Health Care Support Servicereportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥460m |
| Health Care Support Servicereportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥460m |
| Health Care Support Servicereportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥75m |
| —segment total | revenue | 2025-07-01 → 2025-12-31 | ¥2.4bn |
| —segment total | revenue external | 2025-07-01 → 2025-12-31 | ¥2.4bn |
| —segment total | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥17m |
| —segment total | segment profit | 2025-07-01 → 2025-12-31 | ¥404m |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥14m |
| Reconciling Itemsreconciling | revenue external | 2024-07-01 → 2024-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥15m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | −¥159m |
| Clinical Evidence Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥152m |
| Clinical Evidence Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥152m |
| Clinical Evidence Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥19m |
| Functional Cosmetic Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥751m |
| Functional Cosmetic Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥751m |
| Functional Cosmetic Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥25m |
| Functional Food Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| Functional Food Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| Functional Food Retailingreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥4m |
| Functional Food Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | −¥132m |
| Functional Material Developmentreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥183m |
| Functional Material Developmentreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥173m |
| Functional Material Developmentreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥11m |
| Functional Material Developmentreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥3m |
| Health Care Support Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥393m |
| Health Care Support Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥393m |
| Health Care Support Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥39m |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥15m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | −¥45m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 465
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | Prior1InterimDuration | 2683408000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 4377000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 10871000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 15248000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -15248000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 152167000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | 392665000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 751093000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1218352000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 183478000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 2697757000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -14348000 | JPY |
| Net sales | Prior1InterimDuration | 2683408000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 19371000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | 39491000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 25139000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -131746000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 3242000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | -44501000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -158542000 | JPY |
| Operating income | Prior1InterimDuration | -203043000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 131432000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | 460298000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 725202000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 925586000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 170808000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 2413329000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | InterimDuration | 2414229000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 919000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 7069000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 9194000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 17182000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -17182000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 131432000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember | 460298000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 726122000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 932656000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 180002000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 2430511000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -16282000 | JPY |
| Net sales | InterimDuration | 2414229000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |